# Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

> **NCT02877550** · PHASE1 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 25 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02877550
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-15
- **Primary completion:** 2020-04-28
- **Final completion:** 2022-05-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02877550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02877550, "Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02877550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*